Dermatology Enrollment Form: I-Z

InfuCare Rx

Phone: (844) 773-6779
Fax: (844) 533-1131
Website: www.InfuCareRx.com

PATIENT INFORMATION

Name:	SSN#:		
Address:			
City:	State/Zip:		
Telephone:	DOB:	M ☐ F ☐	
Language Preference:	Wt:	Ht:	

PRESCRIBER INFORMATION

Prescribing Practitioner:		NPI:	
Address:			
City		State/Zip	
Office:		DEA:	
Contact:	Phone:	Fax:	

PLEASE FAX COPY OF: ☐ **PRESCRIPTION FRONT & BACK** ☐ **CLINICAL NOTES** ☐ **MEDICAL CARD FRONT & BACK**

PRESCRIPTION

New ☐ Refill ☐ | Ship by: | Ship to: ☐ Patient's Home ☐ Doctor's Office ☐ Other:_____

Drug		Directions and Quantity	Refills
Ilumya™	☐ 100 mg Pre-filled Syringe	☐ **INITIAL:** Inject 100 mg SQ on week 0, and 4 (Qty: 2) ☐ **MAINTENANCE**: Inject 100 mg SQ every 12 weeks (Qty: 1)	
Otezla®	☐ 28 Day Starter Pack	☐ Take as directed per package instructions (Quantity: 55) ☐ 14 day titration starter pack sample provided by MD office	
	☐ Maintenance	☐ Take 30 mg PO twice daily (Quantity: 60) ☐ Take 30 mg PO once daily (Quantity: 30) **Continuation of Therapy:** ☐ Yes ☐ No	
	☐ Bridge Dose Pack	☐ Take 30 mg PO twice daily (Quantity: 28) (12 refills) ☐ Take 30 mg PO once daily (Quantity: 28) (6 refills)	
Siliq™	☐ Pre-filled Syringe	☐ **INITIAL:** Inject 210 mg SQ on weeks 0 & 1 (Quantity: 2) ☐ **MAINTENANCE**: Inject 210 mg SQ every 2 weeks starting at week 2 (Quantity: 2)	
Stelara®	☐ 45 mg Vial (Pediatric ≤ 60 kg) ☐ Pre-filled Syringe ☐ 45 mg ☐ 90 mg Weight Required: _____	☐ **INITIAL:** Inject SQ on day 0 and day 28 (Quantity: 2) ☐ **MAINTENANCE:** Inject SQ every 12 weeks (Quantity:1) ***WEIGHT BASED GUIDELINES*** **PEDIATRIC:** **Less than 60 kg (132.2 lbs): 0.75 mg/kg** **60 kg-100 kg (220 lbs): 45 mg** **Greater than 100 kg (220 lbs): 90 mg** **ADULT:** **Less than or equal to 100 kg (220 lbs): 45 mg** **Greater than 100 kg (220 lbs): 90 mg**	
Taltz®	☐ SureClick® Pen ☐ Mini™ with AutoTouch™	☐ Inject ____ mg (0.8 mg/kg x ___kg SQ every week) **(Less than or equal to 63 kg)** (Quantity: QS 1 month) ☐ Inject 50 mg SQ every week **(Greater than 63 kg)** (Quantity: 4) ☐ Inject 50 mg SQ every week **(Greater than 63 kg)** (Quantity: 4)	
Tremfya™	☐ Pre-filled Syringe	☐ **INITIAL:** Inject 210 mg SQ on weeks 0 & 1 (Quantity: 2) ☐ **MAINTENANCE**: Inject 210 mg SQ every 2 weeks starting at week 2 (Quantity: 2)	

MEDICAL INFORMATION

*****PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY**

Previous Therapies:

	Tried & Failed (Duration):	Not Tolerated:	Contraindication:
☐ Methotrexate	☐ (_____)	☐	_____
☐ Soriatane	☐ (_____)	☐	_____
☐ Clobetasol	☐ (_____)	☐	_____
☐ Hydrocortisone	☐ (_____)	☐	_____
☐ Eucrisa	☐ (_____)	☐	_____
☐ Stelara	☐ (_____)	☐	_____
☐ Humira	☐ (_____)	☐	_____
☐ Enbrel	☐ (_____)	☐	_____
☐ _____	☐ (_____)	☐	_____

PHOTOTHERAPY

	Tried & Failed (Duration):	Not Tolerated:	Contraindication:
☐ UVA/UVB	☐ (_____)	☐	_____

☐ Patient Cannot Afford ☐ Photosensitivity ☐ Risk of skin cancer ☐ Distance from office

☐ L40.Psoriasis Vulgaris (Plaque Psoriasis) ☐ Other: _____

Additional Clinical Information:

☐ Face
☐ Feet
☐ Groin
☐ Hands
☐ Nails
☐ Scalp
☐ Other: _____



Scoring Tool Used

☐ BSI ☐ EASI ☐ SCORAD
☐ POEM ☐ ISGA ☐ % or SCORE _____

Date of Diagnosis: ____/____/_____
☐ Active TB is ruled out: Date: ____/____/_____
☐ Hep B ruled out/treated: Date: ____/____/_____

Allergies:

AMERICAN ACADEMY OF DERMATOLOGY CONSENSUS STATEMENT ON PSORIASIS THERAPIES

☐ Psoriasis is covering greater than 10% body surface area ☐ Psoriasis is on palms, soles, head & neck, or genitals ☐ Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints ☐ Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment, or interpersonal relationships

INJECTION TRAINING

☐ Patient has received pen and injection training ☐ Physician's office to provide injection training ☐ FOSRX/FAST to coordinate injection training

PRESCRIBING PRACTITIONER SIGNATURE

To Prescribing Practitioner: By signing this form and utilizing our services, you are also authorizing FOSRX/FAST to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies and co-pay foundations.

Prescribing Practitioner Signature:	Date: